| CTRI Number |
CTRI/2025/03/082667 [Registered on: 18/03/2025] Trial Registered Prospectively |
| Last Modified On: |
04/03/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Surgical/Anesthesia |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Determination and comparision of effective dose of Propofol combined with Fentanyl and Propofol combined with Remifentanyl in order to find the optimal sedation dose in sedation in Upper Gastrointestinal endoscopic procedures |
|
Scientific Title of Study
|
Optimal Sedation Analgesia In Upper Gastrointestinal
Endoscopic Interventions Determination and Comparison
of Median Effective Target Concentration of Propofol In
Combination With Fentanyl versus Remifentanil PERFS |
| Trial Acronym |
PERFS |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Shikhar More |
| Designation |
Consultant |
| Affiliation |
Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India |
| Address |
Department of Oncoanaesthesiology and Pain,
Phase 1, 2nd floor,
14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India
Kolkata WEST BENGAL 700160 India |
| Phone |
8521890962 |
| Fax |
|
| Email |
shikharmore@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Shikhar More |
| Designation |
Consultant |
| Affiliation |
Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India |
| Address |
Department of Oncoanaesthesiology and Pain,
Phase 1, 2nd floor,
14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India
Kolkata WEST BENGAL 700160 India |
| Phone |
8521890962 |
| Fax |
|
| Email |
shikharmore@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Shikhar More |
| Designation |
Consultant |
| Affiliation |
Consultant, Department of Onco-Anaesthesia and Pain, Tata Medical Center, Kolkata, India |
| Address |
Department of Oncoanaesthesiology and Pain,
Phase 1, 2nd floor,
14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India
Kolkata WEST BENGAL 700160 India |
| Phone |
8521890962 |
| Fax |
|
| Email |
shikharmore@gmail.com |
|
|
Source of Monetary or Material Support
|
| Tata Medical Center, Kolkata.
14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India |
|
|
Primary Sponsor
|
| Name |
Dr Shikhar More |
| Address |
Tata Medical Center, Kolkata
14 MAR(E-W),Newtown,Rajarhat,Kolkata 700160, West Bengal, India |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Shikhar More |
Tata Medical Center |
Endoscopy unit, Phase 2, 14 MAR (E-W), New Town, Rajarhat, Kolkata 700 160, West Bengal, India. North Twentyfour Parganas WEST BENGAL |
8521890962
shikharmore@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Tata Medical Center-Institutional Review Board |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: O||Medical and Surgical, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Fentanyl Bolus |
Fentanyl boluses will be administered along with propofol target controlled infusion for analgesic component. |
| Intervention |
Remifentanil TCI. |
Remifentanil will be administered along with propofol target controlled infusion for analgesic component. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
70.00 Year(s) |
| Gender |
Both |
| Details |
Patients aged 18-70 years undergoing upper GI
endoscopic interventions (ERCP and
EUS-FNA)
ASA (American Society of Anesthesiologists)
physical status I-III. |
|
| ExclusionCriteria |
| Details |
History of allergy to study drugs.
Severe cardiovascular, respiratory, hepatic or renal disease.
Pregnancy and lactation.
BMI less than 18 or more than 35
Psychiatric illness or liver dysfunction leading to altered sensorium
Documented OSA
Anticipated difficult airway |
|
|
Method of Generating Random Sequence
|
Permuted block randomization, fixed |
|
Method of Concealment
|
Case Record Numbers |
|
Blinding/Masking
|
Participant, Investigator and Outcome Assessor Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Incidence of sedation related adverse events (SRAE). |
Periprocedure |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
ED50 and ED90 of propofol in both groups.
Incidence of unsuccessful sedation
Recovery time
Endoscopist satisfaction
Patient satisfaction
Mean total Propofol consumption
|
Periprocedural |
|
|
Target Sample Size
|
Total Sample Size="280" Sample Size from India="280"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
15/04/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Background and purpose Endoscopic retrograde cholangiopancreaticography (ERCP) and endoscopic ultrasound (EUS) are complex and time consuming procedures that require optimal sedation and analgesia. Propofol target controlled infusion (TCI) is commonly used at our institution in combination with either fentanyl bolus or remifentanil TCI. However, there is a paucity in literature regarding the median effective effect site concentration (EC50, Ce) of propofol for sedation in such time consuming endoscopic procedures, especially when used with remifentanil TCI. This study is being proposed to compare propofol fentanyl and propofol remifentanil regimens when used via TCI at the predetermined median effective target concentration (EC50) of propofol. The study will be done in two parts. Part 1 will determine the EC50 and EC95 of propofol with fentanyl and remifentanil combinations. Part 2 of the study will compare the two regimens in terms of efficacy of sedation and incidence of sedation related adverse effects.
Methodology The study will be done in two parts Part 1 Determination of EC50 and EC90 of propofol Participants will be randomly allotted to one of two groups: Group F Fentanyl bolus of 0.5 mcg/kg Group R Remifentanil TCI at Ce of 2 ng/mL The EC50 and EC90 of propofol will be determined for both groups using the Dixon up and down sequential allocation method. The first participant in both will receive an initial effect site concentration (Ce) of 2 mcg/ml. The subsequent participants initial starting Ce will be determined based on the response of the previous participant. Propofol Ce will be increased in step size of 0.5 mcg/mL for rescue in case of unsuccessful sedation. In case of unsuccessful sedation or positive response, the starting Ce of Propofol will be increased by a step size of 0.5 mcg/mL in the subsequent patient. In case of successful sedation or negative response, the starting Ce of Propofol will be decreased by 0.5 mcg/mL in the subsequent patient. Successful sedation is defined as MOASS score 2 Patient does not exhibit gag, cough, purposeful bodily movement throughout the procedure.
Part 2 Randomised controlled trial between the two groups at the determined EC90 of propofol. Participants will be randomly allotted to one of two groups Group F Fentanyl bolus of 0.5 mcg/kg Group R Remifentanil TCI at Ce of 2 ng/mL Both groups of participants will receive propofol TCI at the determined EC90. The primary outcome is the incidence of adverse effects. The secondary outcome will be Recovery Time - Time to regain MOASS 5 after stopping TCI. Endoscopist satisfaction (4 point Likert scale - excellent, good, acceptable and poor) Patient satisfaction (4 point Likert scale - excellent, good, acceptable and poor) Mean total propofol consumption - in mg/kg.
|